Multicenter, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, PK and PD of MK0941 on Postprandial Plasma Glucose Concentrations After Daily Administration MK0941 Before Each Meal in Subjects With T2D Being Treated With Basal Insulin.
Phase of Trial: Phase I
Latest Information Update: 06 Jul 2012
At a glance
- Drugs MK 0941 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 28 Jun 2011 Acutal patient number (70) reported at the 71st Annual Scientific Sessions of the American Diabetes Association.
- 28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
- 07 Apr 2009 Actual patient number (66) added as reported by ClinicalTrials.gov.